Spark Investment Management LLC Increases Position in AnaptysBio, Inc. (NASDAQ:ANAB)
Spark Investment Management LLC increased its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 113.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,100 shares of the biotechnology company’s stock after buying an additional 39,400 shares during the period. Spark Investment Management LLC owned approximately 0.37% of AnaptysBio worth $1,773,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bank of America Corp DE bought a new position in shares of AnaptysBio during the first quarter worth approximately $123,000. TIAA CREF Investment Management LLC bought a new position in shares of AnaptysBio during the first quarter worth approximately $227,000. Endurant Capital Management LP bought a new position in shares of AnaptysBio during the first quarter worth approximately $258,000. Bank of New York Mellon Corp bought a new position in shares of AnaptysBio during the first quarter worth approximately $373,000. Finally, Monashee Investment Management LLC bought a new position in shares of AnaptysBio during the first quarter worth approximately $694,000. Institutional investors and hedge funds own 72.79% of the company’s stock.
Shares of AnaptysBio, Inc. (NASDAQ:ANAB) opened at 22.78 on Tuesday. The company’s market cap is $461.73 million. AnaptysBio, Inc. has a one year low of $15.17 and a one year high of $30.71. The stock’s 50 day moving average is $25.15 and its 200-day moving average is $24.62.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.18) by $0.57. Equities research analysts forecast that AnaptysBio, Inc. will post ($2.48) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Spark Investment Management LLC Increases Position in AnaptysBio, Inc. (NASDAQ:ANAB)” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/08/spark-investment-management-llc-increases-position-in-anaptysbio-inc-nasdaqanab.html.
A number of research analysts have issued reports on the stock. Stifel Nicolaus increased their target price on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, May 2nd. Credit Suisse Group restated an “outperform” rating and set a $34.00 target price on shares of AnaptysBio in a research report on Tuesday, April 18th. Zacks Investment Research upgraded shares of AnaptysBio from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Robert W. Baird assumed coverage on shares of AnaptysBio in a research report on Monday, July 10th. They set an “outperform” rating and a $36.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. AnaptysBio presently has a consensus rating of “Buy” and an average price target of $35.60.
In related news, major shareholder Holdings A/S Novo sold 70,706 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $23.31, for a total transaction of $1,648,156.86. Following the completion of the transaction, the insider now owns 3,009,949 shares of the company’s stock, valued at $70,161,911.19. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total transaction of $901,924.00. The disclosure for this sale can be found here.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio, Inc. (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.